DISEASE BURDEN DURING THE “WATCHFUL WAITING” PERIOD IN WOMEN WITH RECURRENT OVARIAN CANCER IN GERMANY
Author(s)
Harrow B1, Konieczny A2, Pignot M3, Wilk A4, Bala M1
1TESARO, Inc., Waltham, MA, USA, 2TESARO Inc., Waltham, MA, USA, 3Kantar Health, Munich, Germany, 4Team Gesundheit, Essen, Germany
OBJECTIVES: In Europe, use of maintenance therapy is approved to extend the interval between chemotherapy treatments. Still, a substantial number of women with recurrent ovarian cancer are only provided monitoring for signs of recurrence or “watchful waiting”. While studies have shown that patients experience anxiety and fear of recurrence during watchful waiting, the use of healthcare services during watchful waiting has not been examined. This study assesses the rate of these events in Germany using sickness fund data. METHODS: This retrospective study identified patients newly diagnosed with ovarian cancer between January 2010 and December 2012 in a German statutory healthcare fund (BKK) that included full billing information for hospitals, ambulatory sector, and pharmaceuticals. Patients with insurance coverage for 12 months before and ≥1 quarter after first diagnosis were included. Recurrence was defined by the presence of 2nd-line platinum-based therapy, and watchful waiting as the period without active treatment following chemotherapy. The rates of inpatient admissions and outpatient visits during watchful waiting were assessed. RESULTS: During the study period,
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PCN298
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology, Reproductive and Sexual Health
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now